Liraglutide is a human glucagon like peptide-1 (GLP-1) analog, which has 97% sequence homology with human GLP-1. The first original product was developed by Novo Nordisk Nordisk, and was approved to control blood sugar in adult type 2 diabetes patients. Liraglutide not only effectively controls blood sugar, but also has cardiovascular protection and weight loss effects. Its weight loss indications have been approved by the US FDA.
Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.